Skip to main content
Evidence Snapshot

Thymidylate synthase

CHEMBL1952 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-14T03:22:42Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL1952
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Thymidylate synthase as ChEMBL target CHEMBL1952, mapped to UniProt P04818. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Thymidylate synthase
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL1952
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
P04818
Thymidylate synthase
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Thymidylate synthase matters

As of 2026-09-14

Thymidylate synthase is reviewed as Thymidylate synthase (UniProt P04818); Thymidylate synthase shows approved-linked disease relevance led by colorectal cancer. 5 more disease programs remain visible in the same review block.; 8 linked drugs keep this evidence frame grounded.; the current evidence base includes 8 approved drugs, 1038 compounds, and 367 assays, with lead potency reaching pChEMBL 10.4.

Disease context
colorectal cancer

Thymidylate synthase shows approved-linked disease relevance led by colorectal cancer. 5 more disease programs remain visible in the same review block. 8 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include CAPECITABINE, FLOXURIDINE, FLUOROURACIL.

Start review with colorectal cancer because it currently carries approved-linked support. Linked drugs include CAPECITABINE, FLOXURIDINE, FLUOROURACIL, OSI-7904. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Approved-linked 8 linked drugs
Activity base
Portfolio and assay base

ChEMBL currently tracks 8 approved drugs, 1038 compounds, and 367 assays for this target. The dominant activity type is IC50. CHEMBL290277 is the current potency anchor at pChEMBL 10.4.

Use CHEMBL290277 as the tractability anchor when discussing potency (pChEMBL 10.4).

Activity source · ChEMBL 36 via Core Engine
8 approved pChEMBL 10.4
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Thymidylate synthase matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P04818, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why colorectal cancer is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

1038
Total Compounds
367
Total Assays
8
Approved Drugs
IC50: 706.0, KI: 360.0, KD: 4.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL290277
 10.4 Ki —
No preferred name
CHEMBL406575
 10.4 Ki —
No preferred name
CHEMBL295708
 10.1 Ki —
No preferred name
CHEMBL169896
 10.1 Ki Clinical
No preferred name
CHEMBL355323
 10.1 Ki —

Approved Drugs

Structure Compound First Approval
PEMETREXED
CHEMBL225072
 2004
RALTITREXED
CHEMBL225071
 1996
METHOTREXATE
CHEMBL34259
 1953
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-14T03:22:42Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL1952